Browse > Article
http://dx.doi.org/10.4110/in.2013.13.4.123

Metformin Down-regulates $TNF-{\alpha}$ Secretion via Suppression of Scavenger Receptors in Macrophages  

Hyun, Bobae (College of Pharmacy, Sahmyook University)
Shin, Seulmee (College of Pharmacy, Sahmyook University)
Lee, Aeri (College of Pharmacy, Sahmyook University)
Lee, Sungwon (College of Pharmacy, Sahmyook University)
Song, Youngcheon (College of Pharmacy, Sahmyook University)
Ha, Nam-Joo (College of Pharmacy, Sahmyook University)
Cho, Kyung-Hea (Department of Biology, Seoul Women's University)
Kim, Kyungjae (College of Pharmacy, Sahmyook University)
Publication Information
IMMUNE NETWORK / v.13, no.4, 2013 , pp. 123-132 More about this Journal
Abstract
Obesity is consistently increasing in prevalence and can trigger insulin resistance and type 2 diabetes. Many lines of evidence have shown that macrophages play a major role in inflammation associated with obesity. This study was conducted to determine metformin, a widely prescribed drug for type 2 diabetes, would regulate inflammation through down-regulation of scavenger receptors in macrophages from obesity-induced type 2 diabetes. RAW 264.7 cells and peritoneal macrophages were stimulated with LPS to induce inflammation, and C57BL/6N mice were fed a high-fat diet to generate obesity-induced type 2 diabetes mice. Metformin reduced the production of NO, $PGE_2$ and pro-inflammatory cytokines ($IL-1{\beta}$, IL-6 and $TNF-{\alpha}$) through down-regulation of $NF-{\kappa}B$ translocation in macrophages in a dose-dependent manner. On the other hand, the protein expressions of anti-inflammatory cytokines, IL-4 and IL-10, were enhanced or maintained by metformin. Also, metformin suppressed secretion of $TNF-{\alpha}$ and reduced the protein and mRNA expression of $TNF-{\alpha}$ in obese mice as well as in macrophages. The expression of scavenger receptors, CD36 and SR-A, were attenuated by metformin in macrophages and obese mice. These results suggest that metformin may attenuate inflammatory responses by suppressing the production of $TNF-{\alpha}$ and the expressions of scavenger receptors.
Keywords
Metformin; Obesity-induced inflammation; $TNF-{\alpha}$; Scavenger receptors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Flegal, K. M., M. D. Carroll, C. L. Ogden, and L. R. Curtin. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241.   DOI
2 Bae, N. K., I. S. Kwon, and Y. C. Cho. 2009. Ten year change of body mass index in Korean: 1997-2007. Korean J. Obes. 18: 24-30.
3 Mokdad, A. H., E. S. Ford, B. A. Bowman, W. H. Dietz, F. Vinicor, V. S. Bales, and J. S. Marks. 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79.
4 Grundy, S. M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89: 2595-2600.   DOI
5 Shaw, J. E., R. A. Sicree, and P. Z. Zimmet. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes. Res. Clin. Pract. 87: 4-14.   DOI
6 Alberti, K. G. and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553   DOI
7 Shoelson, S. E., L. Herrero, and A. Naaz. 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169-2180.   DOI
8 Qatanani, M. and M. A. Lazar. 2007. Mechanisms of obesityassociated insulin resistance: many choices on the menu. Genes. Dev. 21: 1443-1455.   DOI
9 McArdle, M. A., O. M. Finucane, R. M. Connaughton, A. M. McMorrow, and H. M. Roche. 2013. Mechanisms of obesity- induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front. Endocrinol. (Lausanne). 4: 52.
10 Olefsky, J. M. and C. K. Glass. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72: 219-246.   DOI
11 Kim, J. Y. 2010. Patho-/physiological roles of adipose tissue macrophages. BioWave 12: 1-12.
12 Chawla, A., K. D. Nguyen, and Y. P. Goh. 2011. Macrophage- mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11: 738-749.   DOI
13 Osborn, O. and J. M. Olefsky. 2012. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18: 363-374.   DOI
14 Lumeng, C. N., J. L. Bodzin, and A. R. Saltiel. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117: 175-184.   DOI
15 Patel, P. S., E. D. Buras, and A. Balasubramanyam. 2013. The role of the immune system in obesity and insulin resistance. J. Obes. 2013: 616193.
16 Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U. S. A. 76: 333-337.   DOI
17 Ley, K., Y. I. Miller, and C. C. Hedrick. 2011. Monocyte and macrophage dynamics during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 31: 1506-1516.   DOI
18 Kzhyshkowska, J., C. Neyen, and S. Gordon. 2012. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 217: 492-502.   DOI
19 Baranova I. N., R. Kurlander, A. V. Bocharov, T. G. Vishnyakova, Z. Chen, A. T. Remaley, G. Csako, A. P. Patterson, and T. L. Eggerman. 2008. Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J. Immunol. 181: 7147-7156.   DOI
20 Chen, Y., F. Wermeling, J. Sundqvist, A. B. Jonsson, K. Tryggvason, T. Pikkarainen, and M. C. Karlsson. 2010. A regulatory role for macrophage class A scavenger receptors in TLR4-mediated LPS responses. Eur. J. Immunol. 40: 1451-1460.   DOI
21 Hundal, R. S., M. Krssak, S. Dufour, D. Laurent, V. Lebon, V. Chandramouli, S. E. Inzucchi, W. C. Schumann, K. F. Petersen, B. R. Landau, and G. I. Shulman. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49: 2063-2069.   DOI
22 Yu, H., T. Ha, L. Liu, X. Wang, M. Gao, J. Kelley, R. Kao, D. Williams, and C. Li. 2012. Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-κB activation in macrophages. Biochim. Biophys. Acta. 1823: 1192-1198.   DOI
23 Cai, L., Z. Wang, A. Ji, J. M. Meyer, and D. R. van der Westhuyzen. 2012. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet- induced obesity. PLoS One 7: e36785.   DOI
24 Bailey, C. J. and R. C. Turner. 1996. Metformin. N. Engl. J. Med. 334: 574-579.   DOI
25 Hundal, R. S. and S. E. Inzucchi. 2003. Metformin: new understandings, new uses. Drugs 63: 1879-1894.   DOI
26 Correia, S., C. Carvalho, M. S. Santos, R. Seica, C. R. Oliveira, and P. I. Moreira. 2008. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev. Med. Chem. 8: 1343-1354.   DOI
27 Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk- Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167-1174.   DOI
28 Nath, N., M. Khan, M. K. Paintlia, I. Singh, M. N. Hoda, and S. Giri. 2009. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182: 8005-8014.   DOI
29 Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell, and L. J. Goodyear. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51: 2074-2081.   DOI
30 Lee, S. K., J. O. Lee, J. H. Kim, S. J. Kim, G. Y. You, J. W. Moon, J. H. Jung, S. H. Park, K. O. Uhm, J. M. Park, P. G. Suh, and H. S. Kim. 2011. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. J. Cell. Biochem. 112: 1259-1267.   DOI
31 Tsoyi, K., H. J. Jang, I. T. Nizamutdinova, Y. M. Kim, Y. S. Lee, H. J. Kim, H. G. Seo, J. H. Lee, and K. C. Chang. 2011. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br. J. Pharmacol. 162: 1498-1508.
32 Kalariya, N. M., M. Shoeb, N. H. Ansari, S. K. Srivastava, and K. V. Ramana. 2012. Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 53: 3431-3440.   DOI
33 Yuan, H., L. Li, W. Zheng, J. Wan, P. Ge, H. Li, and L. Zhang. 2012. Antidiabetic drug metformin alleviates endotoxin- induced fulminant liver injury in mice. Int. Immunopharmacol. 12: 682-688.   DOI
34 Kim, H. K. and I. K. Lee. 2006. Endoplasmic reticulum (ER) stress and vascular complication. J. Korean Diabetes. Assoc. 30: 145-150.   DOI
35 Vila-del Sol, V. and M. Fresno. 2005. Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase- 2 expression by IFN-gamma in macrophages. J. Immunol. 174: 2825-2833.   DOI
36 Serhan, C. N. and B. Levy. 2003. Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100: 8609-8611.   DOI
37 Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100: 2417-2423.   DOI
38 Sun, L., J. Liu, D. Cui, J. Li, Y. Yu, L. Ma, and L. Hu. 2010. Anti-inflammatory function of Withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways. J. Cell. Biochem. 109: 532-541.
39 Dinarello, C. A. 2000. Proinflammatory cytokines. Chest. 118: 503-508.   DOI
40 Chi, H., S. P. Barry, R. J. Roth, J. J. Wu, E. A. Jones, A. M. Bennett, and R. A. Flavell. 2006. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 103: 2274-2279.   DOI
41 Opal, S. M. and V. A. DePalo. 2000. Anti-inflammatory cytokines. Chest 117: 1162-1172.   DOI
42 Ma, X. 2001. TNF-alpha and IL-12: a balancing act in macrophage functioning. Microbes. Infect. 3: 121-129.   DOI
43 Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104: 487-501.   DOI
44 Maini, R. N. and P. C. Taylor. 2000. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51: 207-229.   DOI
45 Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A. 91: 4854-4858.   DOI
46 Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756   DOI
47 Charles, K. A., H. Kulbe, R. Soper, M. Escorcio-Correia, T. Lawrence, A. Schultheis, P. Chakravarty, R. G. Thompson, G. Kollias, J. F. Smyth, F. R. Balkwill, and T. Hagemann. 2009. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119: 3011-3023.   DOI
48 Ji, Z. Z., Z. Dai, and Y. C. Xu. 2011. A new tumor necrosis factor (TNF)-$\alpha$ regulator, lipopolysaccharides-induced TNF-$\alpha$ factor, is associated with obesity and insulin resistance. Chin. Med. J (Engl). 124: 177-182.
49 Ziccardi, P., F. Nappo, G. Giugliano, K. Esposito, R. Marfella, M. Cioffi, F. D'Andrea, A. M. Molinari, and D. Giugliano. 2002. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105: 804-809.   DOI
50 Simons, P. J., P. S. van den Pangaart, J. M. Aerts, and L. Boon. 2007. Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J. Endocrinol. 192: 289-299.   DOI
51 Popa, C., M. G. Netea, P. L. van Riel, J. W. van der Meer, and A. F. Stalenhoef. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid. Res. 48: 751-762.   DOI
52 Kleemann, R., S. Zadelaar, and T. Kooistra. 2008. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79: 360-376.   DOI
53 Spagnoli, L. G., E. Bonanno, G. Sangiorgi, and A. Mauriello. 2007. Role of inflammation in atherosclerosis. J. Nucl. Med. 48: 1800-1815.   DOI
54 Skoog, T., W. Dichtl, S. Boquist, C. Skoglund-Andersson, F. Karpe, R. Tang, M. G. Bond, U. de Faire, J. Nilsson, P. Eriksson, and A. Hamsten. 2002. Plasma tumour necrosis factor- alpha and early carotid atherosclerosis in healthy middle- aged men. Eur. Heart. J. 23: 376-383.   DOI
55 Mei, C. L., Z. J. Chen, Y. H. Liao, Y. F. Wang, H. Y. Peng, and Y. Chen. 2007. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-1 macrophage-derived foam cells. Cell. Biol. Int. 31: 1456-1461.   DOI
56 Hashizume, M. and M. Mihara. 2012. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine. 58: 424-430.   DOI
57 Tak, P. P. and G. S. Firestein. 2001. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107: 7-11   DOI